SAVANNAH, Ga. -- Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, ...

The Killian family, of Rockwall, are celebrating a record-breaking fundraising milestone with their annual Sam's Night event, ...

A Pfizer result is unsettling the gene therapy push for Duchenne muscular dystrophy: The boys didn't improve even though a ...

Jefferies initiates buy coverage on Sarepta Therapeutics (SRPT) due to Duchenne muscular dystrophy franchise and strong ...

A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

A TEEN has spent the last 10 years in a wheelchair after he was diagnosed with a rare genetic muscular disease known as ...

On Friday, Capricor Therapeutics (NASDAQ:CAPR) announced 3-year safety and efficacy results from its ongoing HOPE-2 ...

EMA re-confirms non-renewal of conditional marketing authorisation of Duchenne muscular dystrophy medicine, Translarna: Amsterdam, The Netherlands Monday, October 21, 2024, 10:00 ...

Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...

We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...

The agency has reconfirmed its recommendation to not give positive opinion to Translarna (ataluren) after a reexamination of the available data.